The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst firm like HC Wainwright & Co. could instill confidence in investors and potentially lead to a positive short-term impact on Hoth Therapeutics' stock price. The endorsement from a well-regarded analyst underscores the firm's belief in the company's value and prospects.